aveni-ai/aveni-bench-tat-qa huggingface dataset:
Contractual obligations As of December 31, 2019, our contractual obligations were: (1) See "9. Leases" in Item 8 of this Annual Report for additional information. (2) Represents the fixed or minimum amounts due under purchase obligations for hosting services and sales and marketing programs (3) We are unable to reasonably estimate the timing of the cash outflow due to uncertainties in the timing of the effective settlement of tax positions. (4) Represents the maximum funding that would be expected under existing investment agreements with privately-held companies. Our investment agreements generally allow us to withhold unpaid committed funds at our discretion. A detailed discussion and analysis of the fiscal year 2017 year-over-year changes can be found in Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations of our Annual Report on Form 10-K for the year ended December 31, 2018.

Payments due by period

(in thousands)	2020	2021 - 2022	2023 - 2024	2025 and thereafter	Other	Total

Operating lease obligations (1)	19,373	36,373	19,683	1,666	-	$77,095

Purchase obligations (2)	$24,800	$8,129	$438	$ -	$ -	$33,367

Liability for uncertain tax positions (3)	-	-	-	-	5,386	$5,386

Investment commitments (4)	1,754	205	-	-	-	$1,959

Total	$45,927	$44,707	$20,121	$1,666	$5,386	$117,807

Question: What does purchase obligations refer to?
Answer: Represents the fixed or minimum amounts due under purchase obligations for hosting services and sales and marketing programs
Contractual obligations As of December 31, 2019, our contractual obligations were: (1) See "9. Leases" in Item 8 of this Annual Report for additional information. (2) Represents the fixed or minimum amounts due under purchase obligations for hosting services and sales and marketing programs (3) We are unable to reasonably estimate the timing of the cash outflow due to uncertainties in the timing of the effective settlement of tax positions. (4) Represents the maximum funding that would be expected under existing investment agreements with privately-held companies. Our investment agreements generally allow us to withhold unpaid committed funds at our discretion. A detailed discussion and analysis of the fiscal year 2017 year-over-year changes can be found in Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations of our Annual Report on Form 10-K for the year ended December 31, 2018.

Payments due by period

(in thousands)	2020	2021 - 2022	2023 - 2024	2025 and thereafter	Other	Total

Operating lease obligations (1)	19,373	36,373	19,683	1,666	-	$77,095

Purchase obligations (2)	$24,800	$8,129	$438	$ -	$ -	$33,367

Liability for uncertain tax positions (3)	-	-	-	-	5,386	$5,386

Investment commitments (4)	1,754	205	-	-	-	$1,959

Total	$45,927	$44,707	$20,121	$1,666	$5,386	$117,807

Question: What does the company's liability for uncertain tax positions refer to?
Answer: unable to reasonably estimate the timing of the cash outflow due to uncertainties in the timing of the effective settlement of tax positions.
Contractual obligations As of December 31, 2019, our contractual obligations were: (1) See "9. Leases" in Item 8 of this Annual Report for additional information. (2) Represents the fixed or minimum amounts due under purchase obligations for hosting services and sales and marketing programs (3) We are unable to reasonably estimate the timing of the cash outflow due to uncertainties in the timing of the effective settlement of tax positions. (4) Represents the maximum funding that would be expected under existing investment agreements with privately-held companies. Our investment agreements generally allow us to withhold unpaid committed funds at our discretion. A detailed discussion and analysis of the fiscal year 2017 year-over-year changes can be found in Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations of our Annual Report on Form 10-K for the year ended December 31, 2018.

Payments due by period

(in thousands)	2020	2021 - 2022	2023 - 2024	2025 and thereafter	Other	Total

Operating lease obligations (1)	19,373	36,373	19,683	1,666	-	$77,095

Purchase obligations (2)	$24,800	$8,129	$438	$ -	$ -	$33,367

Liability for uncertain tax positions (3)	-	-	-	-	5,386	$5,386

Investment commitments (4)	1,754	205	-	-	-	$1,959

Total	$45,927	$44,707	$20,121	$1,666	$5,386	$117,807

Question: What does the company's investment commitments represent?
Answer: Represents the maximum funding that would be expected under existing investment agreements with privately-held companies
Contractual obligations As of December 31, 2019, our contractual obligations were: (1) See "9. Leases" in Item 8 of this Annual Report for additional information. (2) Represents the fixed or minimum amounts due under purchase obligations for hosting services and sales and marketing programs (3) We are unable to reasonably estimate the timing of the cash outflow due to uncertainties in the timing of the effective settlement of tax positions. (4) Represents the maximum funding that would be expected under existing investment agreements with privately-held companies. Our investment agreements generally allow us to withhold unpaid committed funds at our discretion. A detailed discussion and analysis of the fiscal year 2017 year-over-year changes can be found in Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations of our Annual Report on Form 10-K for the year ended December 31, 2018.

Payments due by period

(in thousands)	2020	2021 - 2022	2023 - 2024	2025 and thereafter	Other	Total

Operating lease obligations (1)	19,373	36,373	19,683	1,666	-	$77,095

Purchase obligations (2)	$24,800	$8,129	$438	$ -	$ -	$33,367

Liability for uncertain tax positions (3)	-	-	-	-	5,386	$5,386

Investment commitments (4)	1,754	205	-	-	-	$1,959

Total	$45,927	$44,707	$20,121	$1,666	$5,386	$117,807

Question: What is the company's total operating lease obligations between 2020 to 2022?
Answer: 55746
Contractual obligations As of December 31, 2019, our contractual obligations were: (1) See "9. Leases" in Item 8 of this Annual Report for additional information. (2) Represents the fixed or minimum amounts due under purchase obligations for hosting services and sales and marketing programs (3) We are unable to reasonably estimate the timing of the cash outflow due to uncertainties in the timing of the effective settlement of tax positions. (4) Represents the maximum funding that would be expected under existing investment agreements with privately-held companies. Our investment agreements generally allow us to withhold unpaid committed funds at our discretion. A detailed discussion and analysis of the fiscal year 2017 year-over-year changes can be found in Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations of our Annual Report on Form 10-K for the year ended December 31, 2018.

Payments due by period

(in thousands)	2020	2021 - 2022	2023 - 2024	2025 and thereafter	Other	Total

Operating lease obligations (1)	19,373	36,373	19,683	1,666	-	$77,095

Purchase obligations (2)	$24,800	$8,129	$438	$ -	$ -	$33,367

Liability for uncertain tax positions (3)	-	-	-	-	5,386	$5,386

Investment commitments (4)	1,754	205	-	-	-	$1,959

Total	$45,927	$44,707	$20,121	$1,666	$5,386	$117,807

Question: What is the percentage constitution of purchase obligations among the total contractual obligations in 2020?
Answer: 54
Contractual obligations As of December 31, 2019, our contractual obligations were: (1) See "9. Leases" in Item 8 of this Annual Report for additional information. (2) Represents the fixed or minimum amounts due under purchase obligations for hosting services and sales and marketing programs (3) We are unable to reasonably estimate the timing of the cash outflow due to uncertainties in the timing of the effective settlement of tax positions. (4) Represents the maximum funding that would be expected under existing investment agreements with privately-held companies. Our investment agreements generally allow us to withhold unpaid committed funds at our discretion. A detailed discussion and analysis of the fiscal year 2017 year-over-year changes can be found in Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations of our Annual Report on Form 10-K for the year ended December 31, 2018.

Payments due by period

(in thousands)	2020	2021 - 2022	2023 - 2024	2025 and thereafter	Other	Total

Operating lease obligations (1)	19,373	36,373	19,683	1,666	-	$77,095

Purchase obligations (2)	$24,800	$8,129	$438	$ -	$ -	$33,367

Liability for uncertain tax positions (3)	-	-	-	-	5,386	$5,386

Investment commitments (4)	1,754	205	-	-	-	$1,959

Total	$45,927	$44,707	$20,121	$1,666	$5,386	$117,807

Question: What is the value of the company's 2023-2024 purchase obligations as a percentage of its total payment due in the 2023-2024 period?
Answer: 2.18
Disaggregated Revenue The table below includes the Company’s revenue for the fiscal year ended September 28, 2019 disaggregated by geographic reportable segment and market sector (in thousands):

Fiscal Year Ended September 28, 2019

Reportable Segment:

AMER	APAC	EMEA	Total

Market Sector:

Healthcare/Life Sciences	$488,851	$602,922	$128,225	$1,219,998

Industrial/Commercial	359,381	534,971	86,868	981,220

Aerospace/Defense	317,558	186,486	84,556	588,600

Communications	256,523	113,329	4,764	374,616

External revenue	1,422,313	1,437,708	304,413	3,164,434

Inter-segment sales	6,995	119,497	5,520	132,012

Segment revenue	$1,429,308	$1,557,205	$309,933	$3,296,446

Question: Which geographic reportable segments does the table provide information for the Company's revenue?
Answer: AMER; APAC; EMEA
Disaggregated Revenue The table below includes the Company’s revenue for the fiscal year ended September 28, 2019 disaggregated by geographic reportable segment and market sector (in thousands):

Fiscal Year Ended September 28, 2019

Reportable Segment:

AMER	APAC	EMEA	Total

Market Sector:

Healthcare/Life Sciences	$488,851	$602,922	$128,225	$1,219,998

Industrial/Commercial	359,381	534,971	86,868	981,220

Aerospace/Defense	317,558	186,486	84,556	588,600

Communications	256,523	113,329	4,764	374,616

External revenue	1,422,313	1,437,708	304,413	3,164,434

Inter-segment sales	6,995	119,497	5,520	132,012

Segment revenue	$1,429,308	$1,557,205	$309,933	$3,296,446

Question: What was the total revenue from the Healthcare/Life Sciences segment?
Answer: 1,219,998
Disaggregated Revenue The table below includes the Company’s revenue for the fiscal year ended September 28, 2019 disaggregated by geographic reportable segment and market sector (in thousands):

Fiscal Year Ended September 28, 2019

Reportable Segment:

AMER	APAC	EMEA	Total

Market Sector:

Healthcare/Life Sciences	$488,851	$602,922	$128,225	$1,219,998

Industrial/Commercial	359,381	534,971	86,868	981,220

Aerospace/Defense	317,558	186,486	84,556	588,600

Communications	256,523	113,329	4,764	374,616

External revenue	1,422,313	1,437,708	304,413	3,164,434

Inter-segment sales	6,995	119,497	5,520	132,012

Segment revenue	$1,429,308	$1,557,205	$309,933	$3,296,446

Question: What was the revenue from AMER for Aerospace/Defense?
Answer: 317,558
Disaggregated Revenue The table below includes the Company’s revenue for the fiscal year ended September 28, 2019 disaggregated by geographic reportable segment and market sector (in thousands):

Fiscal Year Ended September 28, 2019

Reportable Segment:

AMER	APAC	EMEA	Total

Market Sector:

Healthcare/Life Sciences	$488,851	$602,922	$128,225	$1,219,998

Industrial/Commercial	359,381	534,971	86,868	981,220

Aerospace/Defense	317,558	186,486	84,556	588,600

Communications	256,523	113,329	4,764	374,616

External revenue	1,422,313	1,437,708	304,413	3,164,434

Inter-segment sales	6,995	119,497	5,520	132,012

Segment revenue	$1,429,308	$1,557,205	$309,933	$3,296,446

Question: How many geographical segments did external revenue exceed $1,000,000 thousand?
Answer: 2
Disaggregated Revenue The table below includes the Company’s revenue for the fiscal year ended September 28, 2019 disaggregated by geographic reportable segment and market sector (in thousands):

Fiscal Year Ended September 28, 2019

Reportable Segment:

AMER	APAC	EMEA	Total

Market Sector:

Healthcare/Life Sciences	$488,851	$602,922	$128,225	$1,219,998

Industrial/Commercial	359,381	534,971	86,868	981,220

Aerospace/Defense	317,558	186,486	84,556	588,600

Communications	256,523	113,329	4,764	374,616

External revenue	1,422,313	1,437,708	304,413	3,164,434

Inter-segment sales	6,995	119,497	5,520	132,012

Segment revenue	$1,429,308	$1,557,205	$309,933	$3,296,446

Question: What was the percentage constituent of total external revenue to segment revenue?
Answer: 96
Disaggregated Revenue The table below includes the Company’s revenue for the fiscal year ended September 28, 2019 disaggregated by geographic reportable segment and market sector (in thousands):

Fiscal Year Ended September 28, 2019

Reportable Segment:

AMER	APAC	EMEA	Total

Market Sector:

Healthcare/Life Sciences	$488,851	$602,922	$128,225	$1,219,998

Industrial/Commercial	359,381	534,971	86,868	981,220

Aerospace/Defense	317,558	186,486	84,556	588,600

Communications	256,523	113,329	4,764	374,616

External revenue	1,422,313	1,437,708	304,413	3,164,434

Inter-segment sales	6,995	119,497	5,520	132,012

Segment revenue	$1,429,308	$1,557,205	$309,933	$3,296,446

Question: What was the revenue from AMER from Industrial/Commercial as a percentage of the total revenue from Industrial/Commercial?
Answer: 36.63
The following table represents the restricted stock units and SARS stock-based compensation information for the periods indicated (in thousands): (1) Classified as income tax expense within the Consolidated Statements of Operations.

Fiscal Year Ended August 31,

2019	2018	2017

Intrinsic value of SARS exercised	$335	$909	$5,053

Fair value of restricted stock units vested	$49,725	$62,592	$44,010

Tax benefit for stock compensation expense(1)	$611	$1,122	$560

Unrecognized stock-based compensation expense — restricted stock units	$41,778

Remaining weighted-average period for restricted stock units expense	1.3years

Question: What was the Tax benefit for stock compensation expense classified as within the Consolidated Statements of Operations?
Answer: income tax expense
The following table represents the restricted stock units and SARS stock-based compensation information for the periods indicated (in thousands): (1) Classified as income tax expense within the Consolidated Statements of Operations.

Fiscal Year Ended August 31,

2019	2018	2017

Intrinsic value of SARS exercised	$335	$909	$5,053

Fair value of restricted stock units vested	$49,725	$62,592	$44,010

Tax benefit for stock compensation expense(1)	$611	$1,122	$560

Unrecognized stock-based compensation expense — restricted stock units	$41,778

Remaining weighted-average period for restricted stock units expense	1.3years

Question: What was the Tax benefit for stock compensation expense in 2019?
Answer: $611
The following table represents the restricted stock units and SARS stock-based compensation information for the periods indicated (in thousands): (1) Classified as income tax expense within the Consolidated Statements of Operations.

Fiscal Year Ended August 31,

2019	2018	2017

Intrinsic value of SARS exercised	$335	$909	$5,053

Fair value of restricted stock units vested	$49,725	$62,592	$44,010

Tax benefit for stock compensation expense(1)	$611	$1,122	$560

Unrecognized stock-based compensation expense — restricted stock units	$41,778

Remaining weighted-average period for restricted stock units expense	1.3years

Question: What was the Intrinsic value of SARS exercised in 2017?
Answer: $5,053
The following table represents the restricted stock units and SARS stock-based compensation information for the periods indicated (in thousands): (1) Classified as income tax expense within the Consolidated Statements of Operations.

Fiscal Year Ended August 31,

2019	2018	2017

Intrinsic value of SARS exercised	$335	$909	$5,053

Fair value of restricted stock units vested	$49,725	$62,592	$44,010

Tax benefit for stock compensation expense(1)	$611	$1,122	$560

Unrecognized stock-based compensation expense — restricted stock units	$41,778

Remaining weighted-average period for restricted stock units expense	1.3years

Question: What was the change in the Intrinsic value of SARS exercised between 2017 and 2018?
Answer: -4144
The following table represents the restricted stock units and SARS stock-based compensation information for the periods indicated (in thousands): (1) Classified as income tax expense within the Consolidated Statements of Operations.

Fiscal Year Ended August 31,

2019	2018	2017

Intrinsic value of SARS exercised	$335	$909	$5,053

Fair value of restricted stock units vested	$49,725	$62,592	$44,010

Tax benefit for stock compensation expense(1)	$611	$1,122	$560

Unrecognized stock-based compensation expense — restricted stock units	$41,778

Remaining weighted-average period for restricted stock units expense	1.3years

Question: How many years did the Tax benefit for stock compensation expense exceed $1,000 thousand?
Answer: 1
The following table represents the restricted stock units and SARS stock-based compensation information for the periods indicated (in thousands): (1) Classified as income tax expense within the Consolidated Statements of Operations.

Fiscal Year Ended August 31,

2019	2018	2017

Intrinsic value of SARS exercised	$335	$909	$5,053

Fair value of restricted stock units vested	$49,725	$62,592	$44,010

Tax benefit for stock compensation expense(1)	$611	$1,122	$560

Unrecognized stock-based compensation expense — restricted stock units	$41,778

Remaining weighted-average period for restricted stock units expense	1.3years

Question: What was the percentage change in the Fair value of restricted stock units vested between 2018 and 2019?
Answer: -20.56
ITEM 6. SELECTED FINANCIAL DATA In December 2016, we acquired the 67% remaining interest in Inotera and began consolidating Inotera's operating results. In the periods presented above through December 2016, Inotera sold DRAM products exclusively to us through supply agreements. The cash paid for the Inotera Acquisition was funded, in part, with a term loan of 80 billion New Taiwan dollars and $986 million from the sale of 58 million shares of our common stock. See "Item 8. Financial Statements and Supplementary Data – Notes to Consolidated Financial Statements – Acquisition of Inotera."

2019	2018	2017	2016	2015

(in millions, except per share amounts)

Revenue	$23,406	$30,391	$20,322	$12,399	$16,192

Gross margin	10,702	17,891	8,436	2,505	5,215

Operating income	7,376	14,994	5,868	168	2,998

Net income (loss)	6,358	14,138	5,090	(275)	2,899

Net income (loss) attributable to Micron	6,313	14,135	5,089	(276)	2,899

Diluted earnings (loss) per share	5.51	11.51	4.41	(0.27)	2.47

Cash and short-term investments	7,955	6,802	5,428	4,398	3,521

Total current assets	16,503	16,039	12,457	9,495	8,596

Property, plant, and equipment	28,240	23,672	19,431	14,686	10,554

Total assets	48,887	43,376	35,336	27,540	24,143

Total current liabilities	6,390	5,754	5,334	4,835	3,905

Long-term debt	4,541	3,777	9,872	9,154	6,252

Total Micron shareholders' equity	35,881	32,294	18,621	12,080	12,302

Noncontrolling interests in subsidiaries	889	870	849	848	937

Total equity	36,770	33,164	19,470	12,928	13,239

Question: How much of the remaining interests in Inotera that the company acquire in 2016?
Answer: 67%
ITEM 6. SELECTED FINANCIAL DATA In December 2016, we acquired the 67% remaining interest in Inotera and began consolidating Inotera's operating results. In the periods presented above through December 2016, Inotera sold DRAM products exclusively to us through supply agreements. The cash paid for the Inotera Acquisition was funded, in part, with a term loan of 80 billion New Taiwan dollars and $986 million from the sale of 58 million shares of our common stock. See "Item 8. Financial Statements and Supplementary Data – Notes to Consolidated Financial Statements – Acquisition of Inotera."

2019	2018	2017	2016	2015

(in millions, except per share amounts)

Revenue	$23,406	$30,391	$20,322	$12,399	$16,192

Gross margin	10,702	17,891	8,436	2,505	5,215

Operating income	7,376	14,994	5,868	168	2,998

Net income (loss)	6,358	14,138	5,090	(275)	2,899

Net income (loss) attributable to Micron	6,313	14,135	5,089	(276)	2,899

Diluted earnings (loss) per share	5.51	11.51	4.41	(0.27)	2.47

Cash and short-term investments	7,955	6,802	5,428	4,398	3,521

Total current assets	16,503	16,039	12,457	9,495	8,596

Property, plant, and equipment	28,240	23,672	19,431	14,686	10,554

Total assets	48,887	43,376	35,336	27,540	24,143

Total current liabilities	6,390	5,754	5,334	4,835	3,905

Long-term debt	4,541	3,777	9,872	9,154	6,252

Total Micron shareholders' equity	35,881	32,294	18,621	12,080	12,302

Noncontrolling interests in subsidiaries	889	870	849	848	937

Total equity	36,770	33,164	19,470	12,928	13,239

Question: How did Inotera sell DRAM products to Micron in the periods presented in the table through December 2016?
Answer: through supply agreements
ITEM 6. SELECTED FINANCIAL DATA In December 2016, we acquired the 67% remaining interest in Inotera and began consolidating Inotera's operating results. In the periods presented above through December 2016, Inotera sold DRAM products exclusively to us through supply agreements. The cash paid for the Inotera Acquisition was funded, in part, with a term loan of 80 billion New Taiwan dollars and $986 million from the sale of 58 million shares of our common stock. See "Item 8. Financial Statements and Supplementary Data – Notes to Consolidated Financial Statements – Acquisition of Inotera."

2019	2018	2017	2016	2015

(in millions, except per share amounts)

Revenue	$23,406	$30,391	$20,322	$12,399	$16,192

Gross margin	10,702	17,891	8,436	2,505	5,215

Operating income	7,376	14,994	5,868	168	2,998

Net income (loss)	6,358	14,138	5,090	(275)	2,899

Net income (loss) attributable to Micron	6,313	14,135	5,089	(276)	2,899

Diluted earnings (loss) per share	5.51	11.51	4.41	(0.27)	2.47

Cash and short-term investments	7,955	6,802	5,428	4,398	3,521

Total current assets	16,503	16,039	12,457	9,495	8,596

Property, plant, and equipment	28,240	23,672	19,431	14,686	10,554

Total assets	48,887	43,376	35,336	27,540	24,143

Total current liabilities	6,390	5,754	5,334	4,835	3,905

Long-term debt	4,541	3,777	9,872	9,154	6,252

Total Micron shareholders' equity	35,881	32,294	18,621	12,080	12,302

Noncontrolling interests in subsidiaries	889	870	849	848	937

Total equity	36,770	33,164	19,470	12,928	13,239

Question: How was the cash for the Inotera Acquisition raised besides the sale of Micron common stock?
Answer: term loan of 80 billion New Taiwan dollars